SEC Form 4 · accession 0000899243-16-035397
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Ambrogi
Officer — Chief Operating Officer
Period of report
Dec 9, 2016
Accepted (ET)
Dec 13, 2016 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Dec 9, 2016 | S | 5,000 | $8.9336 | D | 289,084 | D | |
| Ordinary SharesF2 | Dec 12, 2016 | S | 10,000 | $9.0442 | D | 279,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 9, 2016, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 5,000 shares in multiple trades at prices ranging from $8.70 to $9.20. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On December 12, 2016, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 10,000 shares in multiple trades at prices ranging from $8.80 to $9.40. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.